Last reviewed · How we verify
Remimazolam Besylate for Injection
Remimazolam Besylate for Injection, developed by The First Affiliated Hospital of Xinxiang Medical College, is a marketed drug with a key composition patent expiring in 2028. Its primary strength lies in its unique mechanism of action, which differentiates it from existing treatments. The primary risk is the lack of clear revenue data and key trial results, which may impact investor confidence and market adoption.
At a glance
| Generic name | Remimazolam Besylate for Injection |
|---|---|
| Sponsor | The First Affiliated Hospital of Xinxiang Medical College |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Step 1 of A Two-step Trial to Evaluate the Effectiveness and Safety of Remimazolam Besylate for Sedation in ICU Patients (PHASE2)
- A Randomized, Controlled Clinical Trial Comparing Remimazolam Besylate Combined With Alfentanil Versus Propofol Combined With Alfentanil for Anesthesia in Thoracic Surgery (PHASE4)
- Sedation Efficacy and Safety of Remazolam Besylate in Ventilated Surgical Critically Ill Patients (PHASE4)
- Remimazolam vs. Midazolam for Sedation and Cognitive Outcomes in Orthopedic Surgery (PHASE3)
- Total Intravenous Anesthesia for Rigid Bronchoscopy Using Remimazolam (NA)
- Remimazolam Versus Midazolam for Sedation During Upper GI Endoscopy: a Randomized Controlled Trial (PHASE4)
- Remimazolam Besylate and Propofol Sedation on Hemodynamic for Coronary Artery Bypass Graft Patients (NA)
- Step 2 of A Two-step Trial to Evaluate the Effectiveness and Safety of Remimazolam Besylate for Sedation in ICU Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: